by Alison Bass | Jul 31, 2008 | Uncategorized
It looks as if the Food and Drug Administration is not the only federal agency in need of a Congress-initiated overhaul. The same Congressmen who recently vowed to strengthen the FDA’s ability to levy fines against drug companies, order drug recalls and restrict...
by Alison Bass | Jul 23, 2008 | Uncategorized
Health Affairs bills itself as “the number one cited health policy journal devoted to publishing original, peer-reviewed research and commentary.” Judging by the journal’s review of my book, Side Effects, its commentary may be original but it sure...
by Alison Bass | Jul 20, 2008 | Uncategorized
A few weeks ago, The Wall Street Journal reported that Sen. Chuck Grassley (R-Iowa) had asked the FDA to re-examine data it had received from GlaxoSmithKline (GSK) way back in 1989 when the drug company first applied for approval of its antidepressant, Paxil. Grassley...
by Alison Bass | Jul 14, 2008 | Uncategorized
Senator Charles Grassley (R-Iowa) is now investigating Martin Keller, chief of psychiatry and the subject of my book,Side Effects: A Prosecutor, a Whistleblower and a Bestselling Antidepressant on Trial, according to Pharmalot. I first wrote about Keller in a 1996...
by Alison Bass | Jul 14, 2008 | Uncategorized
In recent months, Senator Charles Grassley (R-Iowa) has shone a spotlight on the hundreds of thousands, in some cases, millions of dollars that drug companies have paid in speaking and consulting fees to prominent psychiatrists who failed to fully disclose these...
by Alison Bass | Jul 4, 2008 | Uncategorized
Doctors on the take to drug companies seem to be dominating the news of late. Business Week recently chronicled the case of two doctors who touted the long-term use of Chantix and other prescription drugs to curb tobacco cravings in an Annals of Internal Medicine...
